Metformin reverses established lung fibrosis in a bleomycin model

Area of Science:

• Cellular Metabolism
• Pulmonary Fibrosis Research
• Tissue Repair Mechanisms

Background:

• Fibrosis, a pathological repair response, affects organs like the lungs.
• Cellular metabolism critically regulates tissue repair and remodeling.
• AMP-activated protein kinase (AMPK) senses cellular energy and controls metabolic shifts.

Purpose of the Study:

• To investigate the role of AMPK in lung fibrosis.
• To determine if AMPK activation can reverse established fibrosis.

Main Methods:

• Analysis of AMPK activity in human IPF lung tissue and a mouse model.
• Pharmacological activation of AMPK in human IPF myofibroblasts.
• Assessment of fibrosis resolution in a bleomycin-induced mouse model using metformin.

Main Results:

• Lower AMPK activity observed in fibrotic lung regions, linked to apoptosis-resistant myofibroblasts.
• AMPK activation in IPF myofibroblasts reduced fibrotic activity, enhanced mitochondrial biogenesis, and restored apoptosis sensitivity.
• Metformin treatment accelerated fibrosis resolution in mice via an AMPK-dependent pathway.

Conclusions:

• Deficient AMPK activation contributes to non-resolving lung fibrosis.
• Metformin, an AMPK activator, shows therapeutic potential for reversing established fibrosis by promoting myofibroblast deactivation and apoptosis.